Axsome Therapeutics, Inc. (AXSM) Stock
Key stats
- Market cap
- $7.85B
- Price / Earnings ratio
- -47.1x
- EPS (TTM)
- -$3.05
- Volume
- Loading
- 52-week high
- $260.19
- 52-week low
- $123.00
Source: third-party data provider, as of November 13, 2026
Compare with AXSM
Recent news

AXSM Stock Has Slumped Nearly 20% Over The Past Month, But BofA Sees Selloff As Overdone
AXSM Stock Has Slumped Nearly 20% Over The Past Month, But BofA Sees Selloff As Overdone
AXSM

AXSM Stock Hits Fresh 52-Week Lows As Launch Concerns Of Auvelity In Alzheimer's Care Outweigh Q3 Beat
AXSM Stock Hits Fresh 52-Week Lows As Launch Concerns Of Auvelity In Alzheimer's Care Outweigh Q3 Beat
AXSM

What Axsome Therapeutics (AXSM) Said on Its Q3 Earnings Call
What Axsome Therapeutics (AXSM) Said on Its Q3 Earnings Call
AXSM

Axsome (AXSM) Reports Q3 Earnings: What Key Metrics Have to Say
Axsome (AXSM) Reports Q3 Earnings: What Key Metrics Have to Say
AXSM
News tone: automated (AI) classification of the article's content, not a price prediction.
Technical indicators
- RSI 14
- 46.92
- MACD 12/26/9
- -9.86
- EMA 9 of MACD
- -11.82
- MACD histogram
- 1.97
- SMA 50
- $174.09
- Price below SMA 50
- EMA 50
- $167.55
- Price below EMA 50
- SMA 200
- $197.47
- Price below SMA 200
- EMA 200
- $184.33
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Buy
Based on 10 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
The market is expecting earnings per share of $0.24 for this quarter. The company has not yet shared when it is announcing earnings.
Source: third-party data provider
Latest news

AXSM Stock Has Slumped Nearly 20% Over The Past Month, But BofA Sees Selloff As Overdone
AXSM Stock Has Slumped Nearly 20% Over The Past Month, But BofA Sees Selloff As Overdone
AXSM

AXSM Stock Hits Fresh 52-Week Lows As Launch Concerns Of Auvelity In Alzheimer's Care Outweigh Q3 Beat
AXSM Stock Hits Fresh 52-Week Lows As Launch Concerns Of Auvelity In Alzheimer's Care Outweigh Q3 Beat
AXSM

What Axsome Therapeutics (AXSM) Said on Its Q3 Earnings Call
What Axsome Therapeutics (AXSM) Said on Its Q3 Earnings Call
AXSM

Axsome (AXSM) Reports Q3 Earnings: What Key Metrics Have to Say
Axsome (AXSM) Reports Q3 Earnings: What Key Metrics Have to Say
AXSM

Axsome Therapeutics (AXSM) Reports Q3 Loss, Tops Revenue Estimates
Axsome Therapeutics (AXSM) Reports Q3 Loss, Tops Revenue Estimates
AXSM

Could Axsome Therapeutics Turn $5,000 Into $50,000 by 2035?
Could Axsome Therapeutics Turn $5,000 Into $50,000 by 2035?
AXSM

Axsome Therapeutics vs. Moderna: Consistent Revenue Growth or Sharp Volatility
Axsome Therapeutics vs. Moderna: Consistent Revenue Growth or Sharp Volatility
AXSM

Will Axsome Therapeutics (AXSM) Report Negative Earnings Next Week? What You Should Know
Will Axsome Therapeutics (AXSM) Report Negative Earnings Next Week? What You Should Know
AXSM

2 Growth Stocks to Hold for the Next Decade (Hint: These Aren't AI Stocks)
2 Growth Stocks to Hold for the Next Decade (Hint: These Aren't AI Stocks)
AXSM

Will Auvelity Continue to Aid Axsome's Top-Line Growth in Q3?
Will Auvelity Continue to Aid Axsome's Top-Line Growth in Q3?
AXSM
News tone: automated (AI) classification of the article's content, not a price prediction.
About Axsome Therapeutics, Inc.
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products includes AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Dr. Herriot Tabuteau M.D. | Founder, Chairman, CEO & President | 1968 |
| Mr. Nick Pizzie CPA, M.B.A. | Chief Financial Officer | 1975 |
| Mr. Mark L. Jacobson M.A. | Chief Operating Officer | 1983 |
| Mr. Hunter Murdock Esq. | General Counsel & Secretary | 1980 |
| Mr. Ari Maizel M.B.A. | Chief Commercial Officer | 1979 |
| Darren Opland | Director of Corporate Communications | — |
Fundamentals
Valuation
Profitability
Trading
Source: third-party data provider, as of November 13, 2026
Technical indicators
- RSI 14
- 46.92
- MACD 12/26/9
- -9.86
- EMA 9 of MACD
- -11.82
- MACD histogram
- 1.97
- SMA 50
- $174.09
- Price below SMA 50
- EMA 50
- $167.55
- Price below EMA 50
- SMA 200
- $197.47
- Price below SMA 200
- EMA 200
- $184.33
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst views
10 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
- Low
- $220.00
- Average
- $258.30
- High
- $290.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | -10.2 | +13.9 | ||||||||||
| 2022 | -27.5 | -2.3 | +33.6 | -27.7 | -26.6 | +59.4 | -5.0 | +76.9 | -28.7 | -0.4 | +47.9 | +7.2 |
| 2023 | +2.3 | -8.5 | -7.8 | +13.6 | +4.3 | -1.2 | +11.7 | +4.5 | -14.4 | -6.8 | +4.4 | +17.0 |
| 2024 | +16.8 | -12.9 | -3.2 | -4.2 | -1.9 | +7.7 | +7.8 | +3.3 | +0.2 | -1.6 | +10.6 | -14.6 |
| 2025 | +21.9 | +18.7 | -8.3 | +0.6 | -6.3 | -3.0 | -1.5 | +17.7 | -1.6 | +13.8 | +11.6 | +22.6 |
| 2026 | +3.1 | -11.8 | +1.6 | +20.9 | +13.5 | +6.3 | -9.4 | -5.9 | -9.1 | -20.7 | +9.7 |



